<DOC>
	<DOCNO>NCT01363323</DOCNO>
	<brief_summary>This study employ single-center , randomize , double-blind parallel-group design MNTX placebo , positive control ( moxifloxacin ) dose single-blind confirm methodology , normal healthy male female volunteer . Multiple ECGs obtain single clinical supratherapeutic dos MNTX ass ECG effect compare placebo .</brief_summary>
	<brief_title>Effect Methylnaltrexone ( MNTX ) Electrocardiogram ( ECG ) Parameters Cardiac Repolarization</brief_title>
	<detailed_description />
	<mesh_term>Methylnaltrexone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<criteria>1 . Healthy free acute active illness 2 . Males female age 18 45 year , inclusive 3 . Body mass index 1830 , inclusive , weight 50110 kg 4 . ECG within normal limit ( include PR &lt; 220 , QRS &lt; 110 , QTc &lt; 450 ms. ) 1 . Previous MNTX exposure 2 . Currently pregnant nursing 3 . History presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , neurological , medically significant disorder 4 . Consumption alcoholic beverage within 7 day prior study confinement 5 . Any evidence congenital familial longQT syndrome 6 . History drug abuse positive finding urine drug screen 7 . Known allergy hypersensitivity MNTX excipients , moxifloxacin , opioids , related drug history relevant adverse drug reaction origin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>